Wedbush maintains Tyra Biosciences at Outperform, raises price target to $57 from $53

Wedbush reaffirmed its Outperform rating for Tyra Biosciences and increased its price target to $57 from $53, representing a 7.5% rise. This target suggests a potential 171.4% upside from the Nov 10 closing price of $21, according to the firm.

Original reporting
Published Nov 11, 2026, 2:07 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 11, 2026, 2:20 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Wedbush maintains Tyra Biosciences at Outperform, raises price target to $57 from $53 — source image
Decision brief

The 30-second read

$TYRABullishLow
01

Why it matters

The main tradable element is the analyst PT increase, which can influence short-term sentiment but does not introduce new operational or clinical information.

02

Market read

A bullish analyst PT revision may attract incremental speculative interest, but it is unlikely to be a primary driver without new company-specific catalysts.

03

What to watch

Traders may focus more on upcoming trial/regulatory milestones or broader biotech risk appetite than on a single firm’s PT adjustment.

Relevance 4/10Novelty 4/10Timing: today’s analyst note update

Background

The piece reports Wedbush’s rating maintenance and a higher price target for Tyra Biosciences.

Company-level read

Ticker impact

$TYRABullishMedium confidence
Context

Wedbush maintained Tyra Biosciences at Outperform and raised its price target to $57 from $53, implying large upside from the Nov 10 close.

Expected impact

Likely modest upward bias as traders price in the higher target, with follow-through depending on broader biotech sentiment.

Evidence & confidence

The article is an analyst action (PT change) rather than new clinical, regulatory, or financial disclosure; impact is typically limited unless accompanied by new data.

Market effects

Small read-through to biotech sentiment, but no sector-wide catalyst is disclosed.

No specific regional market linkage beyond US biotech sentiment.

No global macro or cross-market linkage mentioned.

Counterpoint

Price-target changes often lag or reflect existing expectations; without new Tyra-specific data, the market may discount the update.

Key entities

  • Tyra Biosciences

    Subject of the analyst action, with Wedbush maintaining Outperform and raising the price target to $57.

  • Wedbush

    Brokerage issuing the rating and price-target change.

Related articles

$TYRAMed

Tyra Biosciences 3Q 2026: EPS ($0.74) — 10-Q Summary

Tyra Biosciences reported a wider net loss in 3Q 2026, with R&D costs rising due to dabogratinib trials and headcount growth. Net loss was $51.12M, and diluted EPS was ($0.74). The company has $700.5M in cash, expected to last through 2030. Dabogratinib trials showed initial positive results.

$TYRAHighAI 8/10

Raymond James reiterates Strong Buy on Tyra Biosciences stock

Raymond James reiterated a Strong Buy rating and $50 price target for Tyra Biosciences (NASDAQ:TYRA) after a discussion with its CEO. The stock trades at $20.93, with analyst targets ranging from $29 to $59. Tyra's lead asset, dabogratinib, showed promising Phase 2 data for non-muscle invasive bladder cancer, with a 100% overall response rate at a 60 mg dose. Raymond James projects $2 billion in combined revenue by 2035 from Tyra's three opportunities.

$TYRAMedAI 8/10

Tyra Biosciences (TYRA) Dabogratinib Delivers 57% Complete Response Rate in Phase 2 Trial. Is Phase 3 Supported?

Tyra Biosciences (TYRA) reported Phase 2 trial results for dabogratinib, showing a 57% complete response rate in patients with FGFR3-altered bladder cancer. The study met its primary endpoint, with 79% objective response rate. The company plans further enrollment and regulatory discussions for Phase 3 design. Safety data showed no severe adverse events at the 60 mg dose.